AP -- Medicines Co. said Wednesday it stopped late-stage testing of cangrelor, an anti-clotting drug candidate, because it was not meeting its goals in two clinical trials.
AP -- Medicines Co. said Wednesday it stopped late-stage testing of cangrelor, an anti-clotting drug candidate, because it was not meeting its goals in two clinical trials.
